Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1

Status

Completed 35Terminated 12Active not recruiting 6Unknown 4Recruiting 2Withdrawn 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 2Fallopian Tube Neoplasms 2Pathologic Complete Response 1Ovarian Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Leiomyosarcoma 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma of the Oesophagus 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × rucaparib × Clear all
NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
72 enrolled 16 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04624178 2025-11-20

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Sarcoma

Leiomyosarcoma

NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT02678182 2025-06-10

PLATFORM

Royal Marsden NHS Foundation Trust

Phase 2 Active not recruiting
494 enrolled
Gastrointestinal

Adenocarcinoma of the Oesophagus

NCT04253262 2025-05-04

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Brown University

Phase 1/2 Active not recruiting
13 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡